CLBIO: Corline's Q1 2025 loss widens, but US market entry and strong clinical data drive optimism

About this update from Corline Biomedical Ab

Q1 2025 saw lower sales and a wider loss, but cost reductions and a strong equity ratio support Corline's US-focused growth strategy. FDA approval for the CHSTM-coated Globe® catheter is expected in H2 2025, with promising clinical results boosting prospects.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Corline Biomedical Ab